Actinogen’s November Alzheimer’s Test Enters Its Final Stage

November Alzheimer’s Readout Remains the Main Catalyst

Actinogen Medical (ASX:ACW) is approaching its most consequential disclosure of the year with the XanaMIA Alzheimer’s trial still scheduled to deliver topline results in November. The final patient visit was completed in late September, bringing the pivotal phase 2b/3 study into its data-finalisation phase rather than generating any indication yet of whether Xanamem met its clinical objectives.

The milestone confirms the timing previously attached to the 247-patient, 36-week placebo-controlled trial, which is testing a once-daily 10 mg dose in people with mild to moderate Alzheimer’s disease selected using clinical criteria and an elevated blood pTau181 biomarker. The company said the immediate priority is to finalise high-quality data and prepare regulatory pathways that could support a further pivotal trial if November’s results are positive. That next stage would most likely involve one or more development partners, according to the announcement.

Open-Label Extension Retains Most Trial Participants

The trial’s open-label extension now has 160 patients receiving active Xanamem, with 87% of participants completing the randomised phase choosing to continue. That is a notable retention figure, but the extension has no placebo control group and is designed primarily to provide longer-term safety and observational information on measures including the CDR-SB dementia scale, cognition and activities of daily living.

The company’s completion update builds on the final XanaMIA patient visit reported in September, when the study’s November timetable was also maintained. Available open-label data are due to be reviewed alongside the topline results, although the extension cannot substitute for the controlled comparison that underpins the pivotal trial’s primary endpoint.

Option Funding Improves Liquidity Before the Data

Actinogen ended September with $15.865 million in cash and cash equivalents after using $6.206 million in operating cash during the quarter. Research and development accounted for $4.332 million of that spend, while staff costs were $1.641 million. Financing inflows of $5.336 million, including $4.566 million from option exercises and $987,000 from equity issuance, partly offset the operating outflow.

The company expects roughly $6 million of net cash from an accrued $10.8 million R&D tax rebate after repaying funding advanced against it. On that basis, it estimates a pro-forma cash balance of about $21.9 million and says its runway could extend to late 2027 or into 2028, provided any new trials are substantially funded through partnerships. The Appendix 4C’s mechanical calculation, based on the quarter’s cash use and period-end cash alone, shows 2.56 quarters of funding, so the longer runway depends on the anticipated rebate, declining XanaMIA costs and the company’s assumptions about future spending.

Patents and Partnering Build the Post-Readout Case

Actinogen also reported first grants for patents covering Xanamem treatment in cognitively normal people in Australia and Israel, as well as manufacturing in China and Chile. The stated expiry dates run to 2040 and 2041 respectively, extending protection around selected uses and production processes rather than changing the current clinical status of the drug.

Commercial discussions with potential global and regional partners continued during the quarter, alongside presentations at industry and scientific conferences. Xanamem remains investigational and is not approved by the FDA or any other global regulatory authority. The immediate question is therefore narrower and more consequential than the broader partnering programme: whether the November data are strong enough to turn this preparation into a credible regulatory and commercial pathway.